EOS006215 + pembrolizumab

EOS006215 + pembrolizumab is an investigational combination therapy currently studied in advanced solid tumors. EOS006215 is a fully human monoclonal antibody that binds to the triggering receptor expressed on myeloid cells 2 (TREM2), aiming to modulate the tumor microenvironment and enhance anti-tumor immunity. Pembrolizumab is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), releasing the brakes on immune responses against tumors. The primary rationale for this combination is to synergistically activate immune pathways—EOS006215 targeting myeloid cell regulation and pembrolizumab targeting T-cell inhibition—to potentially improve anti-tumor efficacy, especially in immunologically “cold” tumors that respond poorly to immunotherapies alone[1][2][4][5].